Modified adenines based on nucleic acid molecule electronics
By using modified 2-amino-7-denitrogenation-adenine in DNA molecular lines, the conductivity of A-T base pairs is improved, and the problems of low conductivity and complex structure in DNA molecular lines are solved, achieving high Conductivity and simplified assembly effects.
Patent Information
- Application Number
- CN202380022034.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-24
- Filing Date
- 2023-01-24
- Publication Date
- 2024-12-06
AI Technical Summary
The conductivity of A-T base pairs in DNA molecular lines is low, resulting in poor charge transfer efficiency and DNA rich in G-C base pairs is prone to form complex structures, affecting the measurement and assembly of molecular devices.
The modified 2-amino-7-deazaadenine (2-amino-7-deazaadenine) is used as a substitute for nucleic acid base pairs, and the conductivity of DNA molecular lines is improved through chemical modification, and density functional theory is used. (DFT) Computing optimizes the structure of base pairs to improve charge transport performance.
It significantly improves the conductivity of DNA molecular lines, overcomes the A-T base barrier, realizes the engineering of highly conductive molecular lines, and simplifies the measurement and assembly process of molecular devices.
Smart Images

Figure CN119095601A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 302,158, filed on January 24, 2022, the entire contents of which are incorporated herein by reference. Background Art
[0003] DNA can transport electrons through its helical structure, which makes it an attractive molecular wire in the field of molecular electronics. DNA has a uniform one-dimensional structure (about 2nm in diameter), programmable self-assembly, so the structure can be designed according to the Watson-Crick base pairing rules (G pairs with C, A pairs with T), and its length can be adjusted from nanometers to micrometers with an accuracy of angstroms.
[0004] However, the conductivity of DNA depends on its sequence, and thymine-adenine (TA) base pairs reduce the conductivity of DNA molecules compared to guanine-cytosine (GC) base pairs. Although homogeneous sequences containing only GC base pairs show relatively high hole mobility in charge transport, the synthesis process is extremely difficult due to the length of the molecule and the high purity required. In addition, GC-rich DNA easily forms unnecessary secondary or even quaternary structures, which complicates the measurement and assembly of DNA-based molecular devices. Therefore, it is necessary to improve the conductivity of AT base pairs used in DNA molecular wires. Summary of the invention
[0005] The present application generally provides modified adenosine with improved conductivity and methods of using the modified AT base pairs in, for example, DNA molecular wires.
[0006] In one aspect, the application features a system including a conductive or semiconductive molecular wire, the system comprising a nanostructure including one or more nucleic acid base pairs, wherein at least one nucleobase within the nanostructure includes 2-amino-7-deaza-adenine or the following:
[0007]
[0008] In another aspect, the application features a system for identifying, characterizing, or sequencing a biopolymer, the system comprising: a nanogap formed by a first electrode and a second electrode; a nanostructure having two ends, the nanostructure comprising one or more nucleic acid base pairs, the nanostructure bridging the nanogap between the electrodes, wherein each electrode is chemically bonded to one of the ends of the nanostructure, and the nanostructure comprises 2-amino-7-deaza-adenine; and a sensing probe attached to the nanostructure, the probe being capable of interacting with the biopolymer or undergoing a chemical or biochemical reaction.
[0009] On the other hand, the present application features a method for improving the conductivity of a molecular wire, comprising: providing a molecular wire, the molecular wire being a nanostructure comprising one or more nucleic acid base pairs; and modifying at least one nucleic acid base to 2-amino-7-deaza-adenine.
[0010] In another aspect, the present application features a method for identifying, characterizing, or sequencing a biopolymer. The method includes: forming a nanogap by placing a first electrode and a second electrode close to each other on a non-conductive substrate or by overlapping each other and separated by a non-conductive layer; providing a nanostructure comprising one or more nucleic acid base pairs having a length comparable to the nanogap, wherein at least one nucleic acid base within the nanostructure is 2-amino-7-deaza-adenine; chemically bonding one end of the nanostructure to the first electrode and chemically bonding the other end of the nanostructure to the second electrode; and attaching a sensing probe to the nanostructure, wherein the sensing probe is capable of physically interacting with or chemically or biochemically reacting with the biopolymer.
[0011] In the above aspects or any embodiment thereof, the molecular wire is electrically connected to an electrode.
[0012] In the above aspects or any embodiment thereof, the molecular wire bridges a nanogap between two electrodes.
[0013] In the above aspects or any embodiment thereof, the molecular wire includes two ends, each end being chemically bonded to one of the electrodes.
[0014] In the above aspects or any embodiment thereof, one of the electrodes is positively charged and the other is negatively charged.
[0015] In the above aspects or any embodiment thereof, the electrodes are disposed on a non-conductive substrate or separated by a non-conductive layer.
[0016] In all of the above aspects or any embodiments thereof, the system includes one or more of the following: a bias voltage applied between the first electrode and the second electrode; a device for recording current fluctuations through the nanostructure, the current fluctuations caused by the interaction between the sensing probe and the biopolymer; and data analysis software for identifying or characterizing the biopolymer or a subunit of the biopolymer.
[0017] In the above aspects or any embodiments thereof, the nanostructure is a nucleic acid duplex, a nucleic acid triplex, a nucleic acid quadruplex, a nucleic acid origami structure or a combination thereof.
[0018] In any of the above aspects or any embodiments thereof, the biopolymer comprises natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide or an analog thereof.
[0019] In all aspects or any embodiment thereof, the sensing probe is a polynucleotide or a polypeptide.
[0020] In all aspects or any embodiments thereof, the sensing probe is a natural, mutated, expressed or synthetic nucleic acid probe, a molecular tweezer, an enzyme, a receptor, a ligand, an antigen and an antibody or a combination thereof.
[0021] In all of the above aspects or any embodiments thereof, the enzyme is a natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase or lactase.
[0022] In all of the above aspects or any embodiments thereof, the nanostructure comprises a polypeptide.
[0023] In all of the above aspects or any embodiments thereof, the polypeptide is a natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase or lactase.
[0024] In the above aspects or any embodiment thereof, the nanogap comprises about 3 to 1000 nm, about 5 to 100 nm, or about 5 to 30 nm.
[0025] In any of the above aspects or any embodiments thereof, the nanogap is 5, 10, 20, 25 or 30 nm.
[0026] In all of the above aspects or any of their embodiments, the electrode contains platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os), iridium (Ir), copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives or their alloys or combinations.
[0027] In the above aspects or any embodiment thereof, the Ta derivative is TiN or TaN.
[0028] In all aspects or any embodiment thereof, the method includes: applying a bias voltage between a first electrode and a second electrode; providing a device for recording current fluctuations through the nanostructure, the current fluctuations caused by the interaction between the sensing probe and the biopolymer; and providing data analysis software for identifying or characterizing the biopolymer or biopolymer subunits.
[0029] In the above aspects or any embodiments thereof, the nanostructure is a nucleic acid duplex, a nucleic acid triplex, a nucleic acid quadruplex, a nucleic acid origami structure or a combination thereof.
[0030] In any of the above aspects or any embodiments thereof, the biopolymer is a natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide or an analog thereof.
[0031] In all aspects or any embodiments thereof, the sensing probe is a natural, mutated, expressed or synthetic nucleic acid probe, a molecular tweezer, an enzyme, a receptor, a ligand, an antigen and an antibody or a combination thereof.
[0032] In all of the above aspects or any embodiments thereof, the enzyme is a natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase or lactase.
[0033] In the above aspects or any embodiment thereof, the size of the nanogap or the distance between two electrodes is about 3 to 1000 nm, preferably about 5 to 100 nm, and most preferably about 5 to 30 nm.
[0034] In any of the above aspects or embodiments thereof, the electrode contains platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os), iridium (Ir), copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives or combinations thereof.
[0035] In any of the above aspects or embodiments thereof, the method involves: providing 2-amino-7-deaza-adenine triphosphate; and enzymatically incorporating the 2-amino-7-deaza-adenine triphosphate into a nucleic acid strand within the nanostructure.
[0036] The present application provides modified adenosine. The compositions and products defined in the present application are made alone or in other ways, and are related to the examples provided below. Other features and advantages of the present application are obvious from the detailed description and claims.
[0037] definition
[0038] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which this application belongs. The following references provide general definitions of many of the terms used in this application for those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (Second Edition, 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, Fifth Edition, R. Rieger et al. (eds.). Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise indicated, the following terms have the meanings assigned to them below.
[0039] The term "adapter" refers to a sequence that is added to a nucleic acid, for example, by connection. The length of the adaptor can be about 5 to about 100 bases, and a sequencing primer binding site (e.g., an amplification primer binding site) and a molecular barcode can be provided, such as a sample identifier sequence or a molecular identifier sequence, preferably a unique identifier sequence. The adaptor can be added to 1) 5' end, 2) 3' end, or 3) both ends of a nucleic acid molecule. A double-stranded adaptor contains a double-stranded end connected to a nucleic acid. An adapter can have an overhang or can be blunt-ended. As will be described in more detail below, a double-stranded adaptor can be newly added to a fragment by connecting only one chain of the adaptor to a fragment. A polymerase can be used to add the sequence of the unconnected chain of the adaptor to a fragment. Y-type adapters and circular adapters are types of double-stranded adapters.
[0040] The term "alteration" refers to a change (increase or decrease) in the structure, activity, or conductivity characteristics of a nucleobase or polynucleotide as detected by standard art-known methods such as those described herein. As used herein, an alteration includes a 10% change in conductivity, a 25% change, a 40% change, a 50%% change in conductivity or greater.
[0041] The term "analog" refers to molecules that are not identical but have similar functional or structural characteristics.
[0042] As used herein, the term "antisense strand" refers to a polynucleotide that is substantially or 100% complementary to a target nucleic acid of interest. For example, the antisense strand can be fully or partially complementary to an mRNA (messenger RNA) molecule, a non-mRNA RNA sequence (e.g., microRNA, piwiRNA, tRNA, rRNA, and hnRNA), or a coding or non-coding DNA sequence. The terms "antisense strand" and "guide strand" are used interchangeably herein.
[0043] In this application, terms such as "comprising", "containing" and "having" have the meanings assigned to them by U.S. patent law, and may mean "including", "comprising", etc.; "consisting essentially of" or "consisting essentially of" also have the meanings assigned to them by U.S. patent law, and the terms are open-ended, allowing for more of the listed contents to exist, as long as the basic or novel features of the listed contents are not changed by the existence of contents other than the listed contents, but excluding embodiments of the prior art.
[0044] The term "complementary" refers to the ability to pair to form a double-stranded nucleic acid molecule or a portion thereof. In one embodiment, the antisense molecule is complementary to a target sequence for the most part. Complementarity need not be perfect, but may include mismatches at 1, 2, 3 or more nucleotides.
[0045] The term "corresponding to" refers to at least a segment comprising a double-stranded gene, such that one strand of the double-stranded inhibitory nucleic acid molecule can bind to the complementary strand of the gene.
[0046] The term "reduction" refers to a decrease of at least about 5% relative to a reference level. The reduction can be 5%, 10%, 15%, 20%, 25% or 50%, and can even be as much as 75%, 85%, 95% or more, and any intermediate percentages.
[0047] The term "detection" refers to identifying the presence, absence, amount or characteristics of an analyte to be detected. In some embodiments, the analyte is modified adenosine. In other embodiments, the conductivity of the modified adenosine is detected using methods known in the art.
[0048] The term "detectable label" refers to a composition that, when attached to a molecule of interest, makes the latter detectable by spectroscopic, photochemical, biochemical, immunochemical or chemical means. For example, useful labels include radioisotopes, magnetic beads, metal beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (e.g., commonly used in ELISA), biotin, digoxigenin or hapten.
[0049] The term "DFT (density functional theory)" refers to the density functional theory for calculating molecular structure and properties. In the present application, the commercially available software SPARTAN (Wavefunction, Inc., USA) is used for DFT analysis. Specifically, the DFT calculations of the present application use the B3LYP / 6-31G* method, as further described in the Spartan'20 Tutorial and User Guide (Wavefunction, Inc., 2022, downloads.wavefun.com / Spartan20Manual.pdf), the entire contents of which are incorporated herein by reference.
[0050] The terms "expression" or "expressed" used herein with respect to a gene refer to the transcription and / or translation product of the gene. The expression level of a DNA molecule in a cell can be determined based on the amount of the corresponding mRNA present in the cell or the amount of the protein encoded by the DNA produced by the cell (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1-18.88). The expression of a transfected gene can occur transiently or stably in a cell. During "transient expression", the transfected gene is not transferred to daughter cells during cell division. Since its expression is limited to transfected cells, the expression of the gene is lost over time. In contrast, stable expression of the transfected gene can occur when the gene is co-transfected with another gene that confers a selective advantage on the transfected cell. This selective advantage may be resistance to a certain toxin presented to the cell.
[0051] The term "fragment" refers to a portion of a polypeptide or nucleic acid molecule. This portion preferably contains at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the full length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides or amino acids.
[0052] The term "high-throughput sequencing" refers to sequencing technologies that allow large numbers of nucleic acids to be sequenced.
[0053] The term "hybridization" refers to hydrogen bonding between complementary nucleobases, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding. For example, adenine and thymine are complementary nucleobases that pair by forming hydrogen bonds.
[0054] The terms "isolated", "purified" or "biologically pure" refer to materials that are separated to varying degrees from components that are normally associated with them in their natural state. The term "isolated" means separated to some extent from the original source or surrounding environment. The term "purified" means a degree higher than separation. The term "purified" or "biologically pure" protein is sufficiently free of other materials so that any impurities do not substantially affect the biological properties of the protein or cause other adverse consequences. That is, if the nucleic acid or peptide of the present application is substantially free of cellular material, viral material or culture medium when produced by recombinant DNA technology or substantially free of chemical precursors or other chemicals when chemically synthesized, the nucleic acid or peptide of the present application is purified. Purity and homogeneity are usually determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can mean that the nucleic acid or protein basically produces a band in the electrophoresis gel. For proteins that can be modified (e.g., phosphorylated or glycosylated), different modifications can produce different isolated proteins, which can be purified separately.
[0055] The term "isolated polynucleotide" refers to a nucleic acid (e.g., DNA) that does not contain genes that flank the genes in the naturally occurring genome of the organism from which the nucleic acid molecule of the present application is derived. Thus, the term includes, for example, recombinant DNA incorporated into a vector; transformed into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or as a separate molecule independent of other sequences (e.g., cDNA or genomic or cDNA fragments generated via PCR or restriction endonuclease digestion). In addition, the term includes RNA molecules transcribed from DNA molecules, and recombinant DNA that is part of a hybrid gene encoding an additional polypeptide sequence.
[0056] The term "isolated polypeptide" refers to a polypeptide of the present application that has been separated from its naturally associated components. Typically, a polypeptide is isolated when at least 60% (by weight) of the polypeptide is free of proteins and naturally occurring organic molecules associated with it. Preferably, the preparation contains at least 75%, more preferably at least 90%, and most preferably at least 99% of the polypeptide of the present application by weight. The isolated polypeptide of the present application can be, for example, extracted from a natural source, obtained by expressing a recombinant nucleic acid encoding such a polypeptide, or by chemically synthesized protein. Purity can be measured by any appropriate method, such as column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
[0057] The term "molecular wire" refers to a molecule or molecular structure that is capable of conducting an electric current.
[0058] The term "nanogap" refers to a gap between two objects, the size of which is in the nanometer range. In one embodiment, the nanogap is formed between two electrodes.
[0059] The term "nanostructure" refers to any structure having one or more dimensions, the dimensions of which are measured in the nanometer range.
[0060] The term "RNA-seq" refers to an RNA sequencing technique for detecting and quantifying RNA molecules in a biological sample, which can be used, for example, to study cellular responses. The related term "scRNA-seq" is single-cell RNA sequencing, which can be, for example, droplet-based single-cell RNA-seq or "Drop-seq", which in the embodiments of the present application is a sequencing technique for analyzing RNA expression in at least hundreds of thousands of individual cells, but any other high-throughput sequencing platform can also be used.
[0061] As used herein, the term "obtaining" as used in "obtaining a reagent" includes synthesizing, purchasing or otherwise obtaining the reagent.
[0062] The term "reduction" refers to a negative change of at least 10%, 25%, 50%, 75% or 100%.
[0063] The term "reference" refers to a standard or control condition. In some embodiments, the conductivity of a polynucleotide comprising one or more modified nucleobases (e.g., modified adenosine) is compared to the conductivity of a reference polynucleotide (e.g., DNA molecule) that does not comprise a modified nucleobase or comprises fewer modified nucleobases (e.g., AT) than the corresponding polynucleotide.
[0064] The term "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence; for example, a fragment of a full-length cDNA or gene sequence or a complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence is generally at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence is generally at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, even more preferably about 100 nucleotides or about 300 nucleotides or any length.
[0065] Nucleic acid molecules that can be used in the methods of the present application include any nucleic acid molecules encoding the polypeptide of the present application or its fragments. Such nucleic acid molecules do not need to be 100% identical to the endogenous nucleic acid sequence, but will generally show substantial identity. Polynucleotides that are "substantially identical" to the endogenous sequence are generally capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. Nucleic acid molecules that can be used in the methods of the present application include any nucleic acid molecules encoding the polypeptide of the present application or its fragments. Such nucleic acid molecules do not need to be 100% identical to the endogenous nucleic acid sequence, but will generally show substantial identity. Polynucleotides that are "substantially identical" to the endogenous sequence are generally capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. "Hybridization" refers to the formation of double-stranded molecules by pairing complementary polynucleotide sequences (e.g., genes described herein) or portions thereof under various stringent conditions (see, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152: 399; Kimmel, AR (1987) Methods Enzymol. 152: 507).
[0066] For example, stringent salt concentrations are typically less than about 750 mM sodium chloride and 75 mM trisodium citrate, preferably less than about 500 mM sodium chloride and 50 mM trisodium citrate, and more preferably less than about 250 mM sodium chloride and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of an organic solvent such as formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, more preferably at least about 50% formamide. Stringent temperature conditions typically include a temperature of at least about 30°C, more preferably at least about 37°C, and most preferably at least about 42°C. It is well known to those skilled in the art to vary additional parameters, such as hybridization time, the concentration of detergents such as sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA. Different degrees of stringency are achieved by combining these different conditions as desired. In a preferred embodiment, hybridization is performed at 30°C in 750 mM sodium chloride, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization is performed in 500 mM sodium chloride, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In a most preferred embodiment, hybridization is performed in 250 mM sodium chloride, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml denatured salmon sperm DNA (ssDNA) at 42° C. Useful variations of these conditions will be apparent to those skilled in the art.
[0067] For most applications, the stringency of the washing step after hybridization will also be different. The stringent conditions for washing can be defined by salt concentration and temperature. As described above, the stringency of washing can be increased by reducing the salt concentration or increasing the temperature. For example, the stringent salt concentration of the washing step is preferably less than about 30mM sodium chloride (NaCl) and 3mM trisodium citrate, and most preferably less than about 15mM sodium chloride (NaCl) and 1.5mM trisodium citrate. The stringent temperature conditions for the washing step generally include a temperature of at least about 25°C, more preferably at least about 42°C, and even more preferably at least about 68°C. In a preferred embodiment, the washing step will be carried out at 25°C in 30mM sodium chloride (NaCl), 3mM trisodium citrate and 0.1% SDS. In a more preferred embodiment, the washing step will be carried out at 42°C in 15mM sodium chloride (NaCl), 1.5mM trisodium citrate and 0.1% SDS. In a most preferred embodiment, the wash step will be performed at 68°C in 15 mM sodium chloride (NaCl), 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0068] "Substantially identical" means that a polypeptide or nucleic acid molecule exhibits at least 50% identity to a reference amino acid sequence (e.g., any amino acid sequence described herein) or nucleic acid sequence (e.g., any nucleic acid sequence described herein). Preferably, such a sequence is at least 60%, more preferably 80% or 85%, more preferably 90%, 95% or even 99% identical in amino acid or nucleic acid to the sequence used for comparison.
[0069] Sequence identity is often measured using sequence analysis software (e.g., Sequence Analysis Software Package, Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by specifying the degree of homology for various substitutions, deletions, and / or other modifications. Conservative substitutions often include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary method for determining the degree of identity, the BLAST program can be used, with a probability score in the range of e -3 and e -100 In between, closely related sequences are indicated.
[0070] The ranges provided herein are to be understood as shorthand for all values within the range. For example, a range of 1 to 50 is to be understood to include any number, combination of numbers, or subrange selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0071] Unless otherwise specified or obvious from the context, as used herein, the term "or" should be understood to be inclusive. Unless otherwise specified or obvious from the context, the terms "a", "an" and "the" as used herein should be understood to be singular or plural.
[0072] The term "vector" refers to a nucleic acid molecule capable of replicating in a host cell, such as a plasmid, cosmid, virus or bacteriophage. In one embodiment, the vector is an expression vector, which is a recombinant or synthetically produced nucleic acid construct with a series of specific nucleic acid components that enable the transcription of the nucleic acid molecule in a host cell. Typically, expression is controlled by certain regulatory components, including constitutive or inducible promoters, tissue-preferred regulatory components and enhancers.
[0073] Unless specifically stated or apparent from the context, as used herein, the term "about" is to be understood as being within the normal tolerance range in the art, such as within 2 standard deviations of the mean. Approximately can be understood as being within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05% or 0.01% of a specified value. Unless the context clearly indicates otherwise, all numerical values provided herein are modified by the term "about".
[0074] The recitation of a list of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of the listed groups. The recitation of an embodiment of a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0075] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] Figure 1 A diagram showing a modified DNA-bridging nanojunction or nanogap between two electrodes is provided, wherein the dots represent modified base pairs.
[0077] Figure 2 The figure provided shows the chemical structure of modified adenine.
[0078] Figure 3 The graphs provided show the HOMO orbitals and energies of standard and modified adenine base pairs calculated according to density functional theory (DFT) using the B3LYP / 6-31G* method (Spartan Software, Wavefunction, Inc., USA).
[0079] Figure 4 The provided figure shows the chemical structure of 2-amino-7-deaza-adenine with proposed modification at the 7-position. DETAILED DESCRIPTION
[0080] The present application provides modified adenosine with improved conductivity, and methods of using the modified AT base pairs in, for example, DNA threads.
[0081] The technology provided herein is based, at least in part, on the discovery of modified adenosines with improved conductivity.
[0082] In one aspect, the present application provides modified adenosine of engineered DNA to overcome the AT base barrier and obtain highly conductive molecular wires ( Figure 1 In the present application, compound 0-1, 2-amino-7-deaza-adenine (in Figure 2 Designated as Da ) as a substitute for adenine. a Can be synthesized by the technology well known in the literature, for example, in "2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine" by Okamoto et al. (Bioorg Med Chem Lett. 12:97-9, 2002). Although the exemplary use of the present application is related to engineered DNA, the disclosed technology is not limited to DNA, and can also be used with RNA, peptide nucleic acid (PNA) molecules and / or any hybrid or chimeric combination of the polynucleotides or oligonucleotides, for example, in DNA / RNA duplexes.
[0083] Density functional theory (DFT) calculations show that D a -D in the T base pair a It has a highest occupied molecular orbital (HOMO) energy level that is higher than the HOMO energy level of A in the AT base pair. Perhaps more importantly, D a It also has a HOMO level that is 0.36 eV higher than the HOMO level of G in the GC base pair ( Figure 3 ). This shows that D a Can serve as an efficient hopping side for DNA charge transport.
[0084] In one embodiment, D a Chemically incorporated into DNA by an automated DNA synthesizer.
[0085] In some embodiments, the present application also includes compound 0-2,2-amino-adenine and compound 0-3,7-deaza-adenine (respectively designated as A a and D, Figure 2 ) as a substitute for adenine in DNA to adjust the conductivity of DNA. a and D have higher HOMO energies than adenine in base pairs ( Figure 3 ). But A a has a HOMO energy level similar to that of G, and D has a lower HOMO energy level than G ( Figure 3 In many embodiments, a stretch of DNA can be engineered so that some or all of the adenines in the DNA have been replaced by D a Some combinations of Aa and D can be substituted. Modified guanine, cytosine, thymidine, uracil, etc. can also be incorporated into any given length of DNA together with the modified adenine of the present application.
[0086] In some embodiments, D a The 7-position is also modified with an R group having beneficial charge transfer properties, such as Figure 4 In many embodiments, R can be, for example but not limited to, alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclopropyl, cyclohexyl, nitro, cyano, and halogenated alkyl groups, aromatic rings such as benzene and five-membered heterocycles, or any combination or derivative thereof.
[0087] On the other hand, the present application also provides modified adenosine triphosphate to enzymatically incorporate the modified adenosine into DNA. An exemplary enzyme for incorporating modified adenosine is a DNA polymerase that can extend a DNA chain with or without a template.
[0088] In another aspect, the present application provides for use in nanogap electronic measurement devices comprising engineered DNA comprising one or more adenosines modified using the methods or schemes discussed in the present application for identification and / or sequencing of biopolymers, such as, but not limited to, devices disclosed in U.S. Patent Publication Nos. 2017 / 0044605A1 and 2018 / 0305727A1, and U.S. Patent Application Nos. 62 / 794,096, 62 / 812,736, 62 / 833,870, 62 / 890,251, 62 / 861,675, and 62 / 853,119. Specifically, the engineered DNA can be used as a nanowire (or molecular wire) or a portion of a nanowire or nanostructure to bridge a nanogap comprising two electrodes, the distance between the two electrodes being in the range of 3 nm to 1 μm, 5 nm to 100 nm, or 5 to 30 nm (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 nm). The nanostructure can be a nucleic acid duplex, a nucleic acid triplex, a nucleic acid quadruplex, a nucleic acid origami structure, or a combination thereof, or other nanostructures composed of nucleic acid bases or a mixture of nucleic acid bases and amino acid bases. The electrodes may include precious metals such as platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os) and iridium (Ir), as well as other metals such as copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives, such as TiN, TaN, etc. or their alloys. Two electrodes may form a nanogap by being placed adjacent to each other on a non-conductive substrate or by being placed overlapping each other and separated by a non-conductive layer, such as described in U.S. Patent Application No. 62 / 890,251. In some embodiments, enzymes may be attached to nanowires or nanostructures to perform biochemical reactions for sensing, identifying or sequencing biopolymers. Exemplary biopolymers for sensing, identifying or sequencing by the device of the present application include, but are not limited to, natural, modified or synthetic DNA, RNA, DNA oligomers, proteins, peptides, polysaccharides, etc. Exemplary enzymes for attachment to the nanowires or nanostructures of the present application include, but are not limited to, DNA polymerases, RNA polymerases, DNA helicases, DNA ligases, DNA exonucleases, reverse transcriptases, RNA primers, ribosomes, sucrases, lactases, and the like, whether natural, mutated, or synthetic.
[0089] In another aspect, the present application provides a system comprising a conductive or semiconductive molecular wire doped with one or more modified adenosines of the present application.
[0090] In another aspect, the present application provides a system for identifying, characterizing or sequencing biopolymers, comprising a nanogap formed by a first electrode and a second electrode placed adjacent to or overlapping each other on a non-conductive substrate, the nanogap being separated by a non-conductive layer; a nanostructure comprising one or more nucleic acid base pairs, one end of which is connected to the first electrode and the other end is connected to the second electrode by a chemical bond, thereby bridging the nanogap, wherein at least one nucleic acid base within the nanostructure is 2-amino-7-deaza-adenine; a sensing probe attached to the nanostructure can interact with the biopolymer or undergo a chemical or biochemical reaction. Also included is a bias applied between the first electrode and the second electrode; a device for recording current fluctuations through the nanostructure caused by the interaction between the sensing probe and the biopolymer; and data analysis software for identifying or characterizing the biopolymer or a subunit of the biopolymer. In another embodiment, the nanostructure is selected from the group consisting of a nucleic acid duplex, a nucleic acid triplex, a nucleic acid quadruplex, a nucleic acid origami structure, and a combination thereof. In another embodiment, the modification of the nucleic acid base reduces the energy gap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) compared to the unmodified standard nucleic acid base of the same position. In another embodiment, the biopolymer is selected from the group consisting of natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide and its analogs. In another embodiment, the sensing probe is selected from the group consisting of natural, mutated, expressed or synthetic nucleic acid probes, molecular tweezers, enzymes, receptors, ligands, antigens and antibodies and their combinations. In another embodiment, the enzyme is selected from the group consisting of DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase and lactase, whether natural, mutated or synthetic. In another embodiment, the nanogap size or the distance between the two electrodes is about 3 to 1000nm, preferably about 5 to 100nm, and most preferably about 5 to 30nm. In another embodiment, the electrode is made of a precious metal selected from platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os), iridium (Ir) or another metal selected from copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives (e.g., TiN, TaN) or alloys, and combinations thereof.
[0091] On the other hand, the present application provides a method for improving the conductivity of a molecular wire, comprising modifying at least one nucleic acid base to 2-amino-7-deaza-adenine.
[0092] In another aspect, the present application provides a method for identifying, characterizing or sequencing a biopolymer, comprising forming a nanogap by placing a first electrode and a second electrode adjacent to each other on a non-conductive substrate or overlapping each other and separated by a non-conductive layer; providing a nanostructure comprising one or more nucleic acid base pairs of length comparable to the nanogap, wherein at least one nucleic acid base within the nanostructure is 2-amino-7-deaza-adenine; connecting one end of the nanostructure to the first electrode and the other end to the second electrode by a chemical bond; and attaching a sensing probe that can interact with the biopolymer or perform a chemical or biochemical reaction to the nanostructure. In another embodiment, the embodiment also includes applying a bias voltage between the first electrode and the second electrode; providing a device for recording current fluctuations through the nanostructure, the current fluctuations being caused by the interaction between the sensing probe and the biopolymer; and providing data analysis software for identifying or characterizing the biopolymer or a subunit of the biopolymer. In another embodiment, the nanostructure is selected from the group consisting of a nucleic acid duplex, a nucleic acid triplex, a nucleic acid quadruplex, a nucleic acid origami structure, and a combination thereof. In another embodiment, the modification of the nucleic acid base reduces the energy gap between the HOMO and the LUMO compared to the unmodified standard nucleic acid base at the same position. In another embodiment, the biopolymer is selected from the group consisting of natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide and its analogs. In another embodiment, the sensing probe is selected from the group consisting of natural, mutated, expressed or synthetic nucleic acid probes, molecular tweezers, enzymes, receptors, ligands, antigens, antibodies and combinations thereof. In another embodiment, the enzyme is selected from the group consisting of natural, mutated or synthetic DNA polymerases, RNA polymerases, DNA helicases, DNA ligases, DNA exonucleases, reverse transcriptases, RNA primers, ribosomes, sucrases and lactases. In another embodiment, the size of the nanogap or the distance between the two electrodes is about 3 to 1000 nm, preferably about 5 to 100 nm, and most preferably about 5 to 30 nm. In another embodiment, the electrode is made of a precious metal selected from the group consisting of platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os) and iridium (Ir), or other metals selected from the group consisting of copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives (such as TiN, TaN) or their alloys and combinations thereof.
[0093] Other embodiments
[0094] From the foregoing description it can be seen that the present application described herein can be changed and modified to adapt to various usages and conditions. Such embodiments are also within the scope of the appended claims.
[0095] The recitation of a list of elements in any variable definition herein includes the definition of the variable as any single element or combination (or subcombination) of the listed elements. The recitation of an embodiment herein includes the embodiment as any single embodiment or in combination with any other embodiment or portion thereof. All patents and publications mentioned in this specification are incorporated herein by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
Claims
1. A system comprising a conductive or semiconductive molecular wire, the system comprising a nanostructure comprising one or more nucleic acid base pairs, wherein: At least one nucleobase within the nanostructure comprises the following:
2. The system of claim 1, wherein: The molecular wire is electrically connected to the electrode.
3. The system of claim 1, wherein: The molecular wire bridges the nanogap between two electrodes.
4. The system of claim 1, wherein: The molecular wire includes two ends, and each end is chemically bonded to one of the electrodes.
5. The system of claim 1, wherein: One of the electrodes is positively charged and the other is negatively charged.
6. The system according to any one of claims 1 to 4, wherein: The molecular wire comprises DNA, RNA, peptide nucleic acid molecules, DNA / RNA duplexes or a combination thereof.
7. A system for identifying, characterizing or sequencing a biopolymer, the system comprising: i. a nanogap formed by a first electrode and a second electrode; ii. a nanostructure having two ends, the nanostructure comprising one or more nucleic acid base pairs, wherein the nanostructure bridges a nanogap between electrodes, each electrode being chemically bound to one of the ends of the nanostructure, and wherein the nanostructure comprises 2-amino-7-deaza-adenine; and iii. Sensing probes attached to the nanostructures, which can interact with the biopolymers or undergo chemical or biochemical reactions.
8. The system of any one of claims 1 to 7, wherein: The electrodes are disposed on a non-conductive substrate or separated by a non-conductive layer.
9. The system of claim 1 or 3, further comprising one or more of the following: iv. a bias voltage applied between the first electrode and the second electrode; v. a device for recording current fluctuations through the nanostructure, the current fluctuations being caused by the interaction between the sensing probe and the biopolymer; and vi. Data analysis software for identifying or characterizing said biopolymer or a subunit of said biopolymer.
10. The system according to any one of claims 1 to 9, wherein: The nanostructure is selected from the group consisting of nucleic acid duplexes, nucleic acid triplexes, nucleic acid quadruplexes, nucleic acid origami structures, and combinations thereof.
11. The system according to any one of claims 1 to 10, wherein: The biopolymer comprises natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide or the like.
12. The system of any one of claims 1 to 10, wherein: The sensing probe is a polynucleotide or a polypeptide.
13. The system of any one of claims 1 to 10, wherein: The sensing probe is selected from the group consisting of natural, mutated, expressed or synthetic nucleic acid probes, molecular tweezers, enzymes, receptors, ligands, antigens and antibodies.
14. The system of claim 13, wherein: The enzyme is selected from the group consisting of natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase and lactase.
15. The system of any one of claims 1 to 14, wherein: The nanostructure also comprises a polypeptide.
16. The system of claim 15, wherein: The polypeptide is selected from the group consisting of natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase and lactase.
17. The system of any one of claims 1 to 14, wherein: The nanogap ranges from about 3 to 1000 nm, about 5 to 100 nm, or about 5 to 30 nm.
18. The system of claim 17, wherein: The nanogap is selected from the group consisting of 5 nm, 10 nm, 20 nm, 25 nm and 30 nm.
19. The system of any one of claims 1 to 18, wherein: The electrode comprises a metal selected from the group consisting of platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os), iridium (Ir), copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta), derivatives thereof, and alloys or combinations thereof.
20. The system of claim 19, wherein: The tantalum derivative is TiN or TaN.
21. A method for improving the electrical conductivity of a molecular wire, comprising: Providing a molecular wire, wherein the molecular wire is a nanostructure comprising one or more nucleic acid base pairs; and At least one nucleic acid base is modified to 2-amino-7-deaza-adenine.
22. A method for identifying, characterizing or sequencing a biopolymer, comprising: i. forming a nanogap by placing a first electrode and a second electrode close to each other on a non-conductive substrate or overlapping each other and separated by a non-conductive layer; ii. providing a nanostructure comprising one or more nucleic acid base pairs having a length comparable to that of the nanogap, wherein at least one nucleic acid base within the nanostructure is 2-amino-7-deaza-adenine; iii. chemically bonding one end of the nanostructure to the first electrode, and chemically bonding the other end of the nanostructure to the second electrode; and iv. Attaching a sensing probe to the nanostructure, wherein the sensing probe is capable of physically interacting with or chemically or biochemically reacting with the biopolymer.
23. The method of claim 23, further comprising: v. applying a bias voltage between the first electrode and the second electrode; vi. providing a means for recording current fluctuations through the nanostructure, the current fluctuations being caused by the interaction between the sensing probe and the biopolymer; as well as vii. providing data analysis software for identifying or characterizing said biopolymer or a subunit of said biopolymer.
24. The method of claim 23, wherein: The nanostructure is selected from the group consisting of nucleic acid duplexes, nucleic acid triplexes, nucleic acid quadruplexes, nucleic acid origami structures, and combinations thereof.
25. The method of claim 23, wherein: The biopolymer is selected from the group consisting of natural, synthetic or modified DNA, RNA, protein, polypeptide, oligonucleotide, polysaccharide and the like.
26. The method of claim 23, wherein: The sensing probe is selected from the group consisting of natural, mutated, expressed or synthetic nucleic acid probes, molecular tweezers, enzymes, receptors, ligands, antigens and antibodies, and combinations thereof.
27. The method of claim 27, wherein: The enzyme is selected from the group consisting of natural, mutant or synthetic DNA polymerase, RNA polymerase, DNA helicase, DNA ligase, DNA exonuclease, reverse transcriptase, RNA primer, ribosome, sucrase and lactase.
28. The method of claim 23, wherein: The size of the nanogap, or the distance between two electrodes, is about 3 to 1000 nm, preferably about 5 to 100 nm, and most preferably about 5 to 30 nm.
29. The method of claim 23, wherein: The electrode includes a metal selected from the group consisting of platinum (Pt), gold (Au), silver (Ag), palladium (Pd), rhodium (Rh), ruthenium (Ru), osmium (Os), iridium (Ir), copper (Cu), rhenium (Re), titanium (Ti), niobium (Nb), tantalum (Ta) and their derivatives or combinations thereof.
30. The method of claim 23, further comprising providing 2-amino-7-deaza-adenine-triphosphate; and enzymatically incorporating the 2-amino-7-deaza-adenine-triphosphate into the nucleic acid strand within the nanostructure.
